FutureChem Co.,Ltd (KOSDAQ: 220100)

Market Cap	331.90B
Revenue (ttm)	15.73B
Net Income (ttm)	-10.57B
Shares Out	22.10M
EPS (ttm)	-478.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,489
Open	15,800
Previous Close	15,720
Day's Range	15,000 - 15,830
52-Week Range	7,960 - 31,250
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 17, 2025

About FutureChem Co.,Ltd

FutureChem Co.,Ltd engages in the research and development, production, and sale of radiopharmaceuticals in South Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a radiopharmaceutical for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303 and 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of athe...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1999
• Employees: 66
• Stock Exchange: KOSDAQ
• Ticker Symbol: 220100

Financial Performance

In 2023, FutureChem Co.,Ltd's revenue was 13.97 billion, an increase of 11.09% compared to the previous year's 12.57 billion. Losses were -6.71 billion, -51.94% less than in 2022.